E. Ohman J or Asset Management AB Boosts Stock Holdings in Boston Scientific Corporation $BSX

E. Ohman J or Asset Management AB boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 42.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 564,471 shares of the medical equipment provider’s stock after purchasing an additional 167,052 shares during the period. Boston Scientific comprises 1.3% of E. Ohman J or Asset Management AB’s holdings, making the stock its 14th largest position. E. Ohman J or Asset Management AB’s holdings in Boston Scientific were worth $53,822,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BSX. Legacy Wealth Asset Management LLC raised its holdings in Boston Scientific by 2.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 20,801 shares of the medical equipment provider’s stock valued at $1,983,000 after acquiring an additional 561 shares during the period. Avanza Fonder AB lifted its holdings in shares of Boston Scientific by 13.1% during the 4th quarter. Avanza Fonder AB now owns 182,979 shares of the medical equipment provider’s stock worth $17,447,000 after acquiring an additional 21,210 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Boston Scientific by 47.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,306,176 shares of the medical equipment provider’s stock worth $410,594,000 after purchasing an additional 1,391,559 shares during the last quarter. Westview Management dba Westview Investment Advisors purchased a new stake in Boston Scientific in the fourth quarter worth approximately $2,363,000. Finally, 180 Wealth Advisors LLC grew its holdings in shares of Boston Scientific by 12.2% during the 4th quarter. 180 Wealth Advisors LLC now owns 6,245 shares of the medical equipment provider’s stock valued at $595,000 after purchasing an additional 681 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.1%

Boston Scientific stock opened at $69.54 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12-month low of $67.56 and a 12-month high of $109.50. The firm has a market capitalization of $103.34 billion, a price-to-earnings ratio of 35.84, a P/E/G ratio of 0.97 and a beta of 0.69. The firm has a 50 day moving average of $79.22 and a 200 day moving average of $91.68.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BSX. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a research note on Thursday, February 5th. National Bank Financial set a $115.00 target price on Boston Scientific in a report on Monday, February 2nd. Finally, Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $106.27.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.